No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 30 of the 40 quarters in the window, leaving 10 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 10.9x · 10Y median 12.1x · 46th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:32:42.127Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:32:42.127Z. Latest historical point 2023-03-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:32:42.127Z. Latest historical point 2023-03-10.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:32:42.127Z. Latest historical point 2023-03-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Lipocine Inc. (LPCN) stock was $2.08 as of Oct 6, 2026, 10:27 AM EDT, up 0.48% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -38.1% · 3-year avg -9.4%/yr · 5-year avg -34.8%/yr
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions.
Biotechnology · Salt Lake City, UT
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.39
Revenue Est.
$159500.00
Last Quarter Results
EPS
$-0.32
vs Estimate
$-0.40
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LPCN | $17.15M | $2.08 | +0.48% | -38.07% | -34.76% | -29.99% | N/A |
| 2DYAI | $16.85M | $0.46 | +1.85% | -60.69% | -38.53% | -11.56% | vs LPCN |
| 3MRKR | $17.51M | $1.05 | -0.94% | +11.06% | -42.13% | -33.25% | vs LPCN |
| 4BNGO | $16.64M | $1.45 | +0.35% | -24.38% | -78.37% | N/A | vs LPCN |
| 5BCDA | $15.93M | $1.07 | -1.83% | -19.72% | -61.39% | -46.74% | vs LPCN |
| 6ALLR | $15.60M | $0.98 | -1.98% | -38.75% | N/A | N/A | vs LPCN |
N/A
$190099.00
vs Estimate
$213000.00
Consensus Rating
Based on 2 analysts
Average Price Target
$5.00
+140.4% upside
Low
$4.00
Current
$2.08
High
$6.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.46 | $-0.35 | $-0.25 | 1 |
| Quarter ending Dec 2026 | $-0.48 | $-0.36 | $-0.25 | 1 |
| Quarter ending Mar 2027 | $-0.37 | $-0.28 | $-0.19 | 1 |
| Quarter ending Jun 2027 | $-0.37 | $-0.28 | $-0.19 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.93 | $-1.54 | $-1.16 | 1 |
| FY 2027 | $-1.67 | $-1.34 | $-1.01 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $121523.00 | $159500.00 | $197476.00 | 1 |
| Quarter ending Dec 2026 | $123809.00 | $162500.00 | $201190.00 | 1 |
| Quarter ending Mar 2027 | $76190.00 | $100000.00 | $123809.00 | 1 |
| Quarter ending Jun 2027 | $76190.00 | $100000.00 | $123809.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $509931.00 | $631248.00 | $752564.00 | 1 |
| FY 2027 | $601822.00 | $745000.00 | $888177.00 | 1 |
